Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
Anika Therapeutics | 10-Q: Q3 2024 Earnings Report
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript Summary
Anika Therapeutics Is Maintained at Outperform by Barrington Research
Anika Therapeutics Analyst Ratings
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Cuts Target Price to $25
The Market Doesn't Like What It Sees From Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Revenues Yet As Shares Tumble 32%
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
12 Health Care Stocks Moving In Thursday's Intraday Session
Executive Management From Primo Medical Group Along With Others, Combined to Acquire Arthrosurface From Anika Therapeutics >ANIK
Press Release: Arthrosurface Returns to It Roots Following Divestiture From Anika Therapeutics
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
Express News | Anika Therapeutics Inc: Outlook FY 2024 Commercial Channel Rev up 14%-19% Excluding Revenue From Discontinued Ops
Anika Therapeutics Expects One-Time Cash Restructuring and Transaction Charges Between $3M to 5 M >ANIK
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q3 Revenue $38.8M
Anika Therapeutics Plans Concentrate Capital and Resources on Core HA Technology >ANIK
Anika Therapeutics: Sale of Arthrosurface for $10M Closed Oct 31
Express News | Anika Therapeutics Q3 Income From Operations USD -28.017 Million
Express News | Anika Therapeutics Q3 Net Income USD -29.918 Million
Express News | Anika Therapeutics Q3 Pretax Profit USD -27.611 Million